Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122067 | 0.84 | PTGS2 (0.49) | PTGS2PTGS1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL7322949 | 0.82 | PTGS2 (0.51) | PTGS2PTGS1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL7316270 | 0.80 | PTGS1 (0.58) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL3561929 | 0.79 | PTGS2 (0.50) | PTGS2PTGS1ALDH1A1KDM4ECYP2C9 | |
| SCHEMBL3561092 | 0.77 | TRPC3 (0.51) | PTGS2PTGS1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL28825739 | 0.76 | TRPC3 (0.44) | DRD1PTGS2PTGS1ALDH1A1NPSR1 | |
| SCHEMBL3564656 | 0.75 | ALDH1A1 (0.45) | PTGS1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL3560874 | 0.73 | ALDH1A1 (0.42) | PTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL3560876 | 0.73 | ALDH1A1 (0.42) | PTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL22122130 | 0.73 | PTGS2 (0.46) | DRD1PTGS2PTGS1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705029-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705029-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705029-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1732900-A4 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-22 | — | — | US | disclosed |
| US-7202232-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202232-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202232-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1732900-A2 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050272699-A1 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2005-12-08 | — | — | US | disclosed |
| WO-2005091752-A2 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272699-A1 | Acrylonitrile derivatives for inflammation and immune-related uses | IL1B, IL6, TLR4 | DRD1 4827/4885PTGS2 323/4885PTGS1 207/4885 |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | IL1B, IL6, TLR4 | DRD1 4827/4885PTGS2 323/4885PTGS1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.